Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: An indirect treatment comparison

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Freemantle, Nick ^a   Ginsberg, David A ^b   McCool, Rachael ^c   Fleetwood, Kelly ^d   Arber, Mick ^c   Khalaf, Kristin ^e,f   Loveman, Clara ^g   Ni, Quanhong ^e,h   Glanville, Julie ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

^d Logan Building   (United Kingdom)

^e ALLERGAN INC   (United States)

^f XCENDA   (United States)

^g ALLERGAN PLC   (United States)

^h CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MIRABEGRON; ACETANILIDE DERIVATIVE; THIAZOLE DERIVATIVE; URINARY TRACT AGENT;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS; MICTURITION; NOCTURIA; OVERACTIVE BLADDER; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; COMPARATIVE STUDY; DRUG EFFECTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

ACETANILIDES; BOTULINUM TOXINS, TYPE A; HUMANS; NOCTURIA; THIAZOLES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINATION; UROLOGICAL AGENTS;

EID: 84960398542     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009122     Document Type: Article

References (49)

1. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009;28:287.
2. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-9.
3. Rackley RR, Vasavada SP, Firoozi F, et al. Neurogenic bladder. Medscape, 2009. http://emedicine.medscape.com/article/453539-overview #a11 (accessed Aug. 2014).
4. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U. S.community-based survey. Urology 2001;57:1044-50.
5. Tromp AM, Smit JH, Deeg DJ, et al. Predictors for falls and fractures in the longitudinal aging study Amsterdam. J Bone Miner Res 1998;13:1932-9.
6. Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011;59:387-400.
7. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-63.
8. Leong RK, De Wachter SG, Van Kerrebroeck PE. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010;84:245-53.
9. National Institute for Health and Care Excellence (NICE). NICE clinical guideline 171. Urinary incontinence: the management of urinary incontinence in women. London: NICE, 2013. http://www.nice.org.uk/guidance/cg171/chapter/recommendations (accessed Aug. 2014).
10. Chancellor MB, Levanovich P, Rajaganapathy BR, et al. Optimum management of overactive bladder: Medication vs Botox® vs InterStim® vs Urgent® PC. Urol Pract 2014;1:7-12.
11. Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn 2011;30:1448-55.
12. Abrams P, Manson J, Kirby MG. Incidence and epidemiology of storage lower urinary tract symptoms. Eur Urol Rev 2012;7:50-4.
13. BOTOX. Approved label. Suppl. 5251 (01/18/2013). http://www.accessdata.fda.gov (accessed Aug. 2014).
14. Summary of Product Characteristics: BOTOX, Allergan Ltd. May 2014. http://www.medicines.ie (accessed Aug. 2014).
15. Summary of Product Characteristics: BOTOX, Allergan Ltd. January 2014. http://www.mhra.gov. uk (accessed Aug. 2014).
16. Betmiga: EPAR-Product Information. http://www.ema.europa.eu (accessed Aug. 2014).
17. Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65.
18. Papanicolaou P, McKendrick J, Deem M, et al. Systematic literature review of the burden of (idiopathic) overactive bladder. Fleet, Hampshire: PRMA Consulting, 2013.
19. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3:80-97.
20. Australian Pharmaceutical Benefits Advisory Committee (PBAC) Indirect Comparisons Working Group. Report of the indirect comparisons working group to the pharmaceutical benefits advisory committee: assessing indirect comparisons. Canberra: Australian Department of Health and Ageing, PBAC, 2009.
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
22. Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: Decision Support Unit, 2011.
23. Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249-56.
24. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186-93.
25. Lunn DJ, Thomas A, Best N, et al. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
26. Altaweel W, Mokhtar A, Rabah DM. Prospective randomized trial of 100u vs 200u BOTOX® in the treatment of idiopathic overactive bladder. Urol Ann 2011;3:66-70.
27. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-22.
28. Cohen BL, Barboglio P, Rodriguez D, et al. Preliminary results of a dose-finding study for botulinum toxin-a in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009;28:205-8.
29. Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520-9.
30. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxina for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010;184:2416-22.
31. King J, Neville J. A randomised, double-blind, placebo-controlled trial of botulinum toxin type A injections for the treatment of refractory idiopathic detrusor overactivity[abstract]. Int Urogynecol J Pelvic Floor Dysfunct 2007;18(Suppl 1):S77.
32. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-6.
33. Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507-14.
34. Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs.onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med 2012;367:1803-13.
35. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95.
36. Astellas. A Phase 2, double blind, placebo controlled, parallel group study of YM 178 in patients with overactive bladder (178-CL-045). Clinical Study Report Synopsis. Bethesda, MD: Astellas, 2009.
37. Astellas. A randomized, double blind, parallel group, proof-of-concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder (BLOSSOM) 178-CL-008. Clinical Study Report Synopsis. Bethesda, MD: Astellas, 2006.
38. 3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20.
39. Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447-58.
40. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β (3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95.
41. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a (3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305.
42. Yamaguchi O, Hidehiro K, Yukio H, et al. A phase III, randomized, double-blind, placebo and active controlled study of once-daily mirabegron 50 mg in patients with overactive bladder[abstract]. Urology 2012;80(Suppl 1):S10.
43. Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. London: National Institute of Health and Care Excellence, 2011.
44. Andersson KE. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxin A. Ther Clin Risk Manag 2013;9:161-70.
45. Drake M, Ginsberg D, Gruenenfelder J, et al. Onabotulinumtoxin A improves the symptoms of urgency and incontinence and provides treatment benefit in patients with overactive bladder regardless of incontinence severity at baseline. Eur Urol Suppl 2015;2:e148.
46. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Syn Meth 2012;3:80-97.
47. Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;(12): CD005493.
48. Nitti VW, Khullar V, Van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32.
49. Cui Y, Zong H, Yang C, et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 2014;46:275-84.